U.S. Markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
67.79+0.33 (+0.49%)
At close: 4:00PM EST
Sign in to post a message.
  • w
    "Merck's COVID-19 pill shows lower efficacy in updated data"
  • J
    So new covid variant.... yeah this is not over.... the unvaccinated in hospital..... win for Gilead and Remdesivir.... strong buy
  • M
    25th November 2021 – (Hong Kong) According to Sky News, A new variant of the coronavirus with a “constellation” of mutations has been identified in Botswana. Designated as B.1.1.529, scientists are still unclear whether existing antibodies would react well to the variant – which has 32 spike protein mutations. Spike proteins are what viruses use to get into human cells, and some of the vaccines work by training the body to recognise the spikes and neutralise them. Mutations on the spike can therefore potentially prove problematic for mRNA doses, like Pfizer and Moderna. However, with only a handful of recorded cases – three in Botswana, six in South Africa and one in Hong Kong from someone who travelled from South Africa, scientists are hopeful that COVID cases caused by the new virus specimen will not be widespread
  • T
    What would we wait for Gilead in the future. I meant 4 th quarter 2021.
    1) on the up side. The upsellings of Trodelvy, the filing of Magrolimab, and The good or recorded sellings of Remy.
    The best I guess Gild may climb up to 75 and stay at 80 after earning.
    2) on the down side, if Pfizer’s or Merck’s pills get FDA. Surely, Gilead would go down until quarter reports later showing that Gild revenues still move forward with or with out those pill causes.
    Then, I guess Gilead would go to the range 60-65. I lean to FDA decisions would be next year.
    I am in for Gilead long investment not because of Remy. I believe in their oncology strategy.
    I would be hit when the downside come. I guess the upside come first, then the down side , and finaly the more permanent up sides. So, I adjust my investment in Gilead along with what I see. I am already bought back all my put options $60. Got some gains but I brought a little soon. Does not matter as long as I got some in the last down side so my Gilead shares could build up. Now I start selling Gilead call options at 77.5 and take $1 per share due sometime in next Feb. I think it is pretty safe for gild price not to go over and I still can get those free bucks. This operation is just start and I will sell more if gild goes up $2-3 bucks from 70. Those cycles I do it repeatedly in last 2 years. It works with gilead.
  • R
    Another Variant found in South Africa ?? Hurry up Remdesivir in pill 💊 form ….
  • D
    There is little value left in this overpriced market. I have been adding to my GILD, BMY, MO, VZ and PSX positions. All 5 of these stocks are way undervalued at current pricing.
  • K
    Even though we are about 1/3 of our real value, don't complain! At least it's a little traction. We can sell at $140 or higher!
  • J
    09:18 AM EST, 11/18/2021 (MT Newswires) -- Gilead Sciences (GILD) and Arcus Biosciences (RCUS) said Thursday that Gilead has decided to exercise its options to three programs in Arcus' clinical-stage portfolio, with the latter set to receive option payments of $725 million.
    These programs included potential small-lung cancer treatment domvanalimab, potential colon and prostate cancer drug etrumadenant and drug candidate for pancreatic ductal adenocarcinoma quemliclustat.
    If the optioned molecules achieve regulatory approval, Gilead and Arcus will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive rights outside the U.S. and Gilead will pay to Arcus tiered royalties.
    Price: 67.53, Change: +0.07, Percent Change: +0.10 Copyright © 2021 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibite.
  • D
    GILD is a $100 stock trading at $70. The market is soon going to turn and favor all the good dividend stocks that have underperformed. GILD, PSX, MO, VZ and BMY will be the ones to be in once the market realizes how undervalued these companies are.
  • D
    A Small company TNXP published data on Sangivamycin to replace use of Remdesivir from Gilead Science in laboratory-based assays against multiple variants of SARS-CoV-2 cases ........Nov 23 ,2021

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of "Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties," in JCI Insight. The paper includes in vitro studies that show sangivamycin, the active pharmaceutical ingredient in the Company's (TNX-3500) product candidate, is a potent antiviral against SARS-CoV-2, the cause of COVID-19, and suppresses viral replication in tissue culture with greater efficacy than remdesivir, the active pharmaceutical ingredient of Gilead Sciences, Inc.'s Veklury®. When tested in combination with remdesivir, both drugs had additive rather than competitive effect against SARS-CoV-2. The new data show that TNX-3500 has similar low nanomolar antiviral activity in laboratory-based assays against multiple variants of SARS-CoV-2, including the Delta variant. The article can be accessed at
  • J
    Whatever became of the ‘inhaler’ Remdesivir that Gild said earlier was being worked on … still in the works?
  • T
    When is the next dividend payday? December 30? Wow I just collect the last one just like yesterday. Time really goes by. Can’t wait. O’Day is better pay me 0.75 if next earning does good.
    Any comment on the drug they filed today?
  • G
    I must have missed the news that Pfizer and Moderna are going to give billions of dollars of free vaccines and booster shots. Boy are they lucky to have CEO'S that actually care about shareholders.
  • a
    a a
    $ATNM conversation
    As per ejny23: huge news
    #SITC21 Actimab A with @GileadSciences @FortySeven
    $FTSV Magrolimab #CD47 immunotherapy combo’s shown strong efficiency in AML & solid tumors. Partnership/acquisition potentially
    Reminder $FTSV acquired by $Gild for $4.9B, for CD47 and radiotherapy technology
  • J
    This should be up 5%
  • L
    Lucky Lee
    Good news on Trodelvy!

    Trodelvy Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

    Trodelvy is approved in Australia, Canada, Great Britain, Switzerland, and the United States in metastatic TNBC. Regulatory review is also underway in Singapore and China with applications submitted by Everest Medicines
  • B
    Does Gilead and MTNB own a potential "golden goose" in their Oral LNC formulation of Remdesivir ?

    Soon we will find out

  • C
    Gilead Sciences Says European Commission Grants Marketing Authorization To Breast Cancer Treatment.
  • J
    How in god's name is this red
  • c
    If you’re looking for a short and sweet guide to the day’s biggest news, I recommend ( They breakdown the most important pre-market news and it only takes a few minutes to read.